DE60325946D1 - Modifizierter typ-1-plasminogenaktivatorinhibitor und darauf beruhende verfahren - Google Patents

Modifizierter typ-1-plasminogenaktivatorinhibitor und darauf beruhende verfahren

Info

Publication number
DE60325946D1
DE60325946D1 DE60325946T DE60325946T DE60325946D1 DE 60325946 D1 DE60325946 D1 DE 60325946D1 DE 60325946 T DE60325946 T DE 60325946T DE 60325946 T DE60325946 T DE 60325946T DE 60325946 D1 DE60325946 D1 DE 60325946D1
Authority
DE
Germany
Prior art keywords
pai
modified
angiogenesis
analogs
derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60325946T
Other languages
English (en)
Inventor
Rafal Swiercz
Steven H Selman
Jerzy Jankun
Ewa Skrzypczak-Jankun
Joanna Chorostowska-Wynimko
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Toledo
Original Assignee
Medical College of Ohio
University of Toledo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medical College of Ohio, University of Toledo filed Critical Medical College of Ohio
Application granted granted Critical
Publication of DE60325946D1 publication Critical patent/DE60325946D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C07K14/8121—Serpins
    • C07K14/8132—Plasminogen activator inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
DE60325946T 2002-03-04 2003-03-04 Modifizierter typ-1-plasminogenaktivatorinhibitor und darauf beruhende verfahren Expired - Lifetime DE60325946D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US36167002P 2002-03-04 2002-03-04
PCT/US2003/006679 WO2003080646A2 (en) 2002-03-04 2003-03-04 Modified plasminogen activator inhibitor type-1 and methods based thereon

Publications (1)

Publication Number Publication Date
DE60325946D1 true DE60325946D1 (de) 2009-03-12

Family

ID=28454581

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60325946T Expired - Lifetime DE60325946D1 (de) 2002-03-04 2003-03-04 Modifizierter typ-1-plasminogenaktivatorinhibitor und darauf beruhende verfahren

Country Status (7)

Country Link
US (2) US7592422B2 (de)
EP (1) EP1487867B1 (de)
AT (1) ATE421528T1 (de)
AU (1) AU2003243134A1 (de)
CA (1) CA2481556C (de)
DE (1) DE60325946D1 (de)
WO (1) WO2003080646A2 (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE421528T1 (de) * 2002-03-04 2009-02-15 Ohio Med College Modifizierter typ-1-plasminogenaktivatorinhibitor und darauf beruhende verfahren
US8106002B2 (en) 2005-04-18 2012-01-31 Chugai Seiyaku Kabushiki Kaisha Anti-cancer agent comprising protein C inhibitor
US20090041755A1 (en) * 2005-05-10 2009-02-12 Ludwig Institute For Cancer Research Methods and Compositions For PDGF-D Activation and Inhibition
WO2007047205A2 (en) * 2005-10-11 2007-04-26 Amano Enzyme Usa Co., Ltd. Enzyme inhibitors of pai-1
WO2009014564A2 (en) * 2007-04-27 2009-01-29 The University Of Toledo Modified plasminogen activator inhibitor type-1 molecule and methods based thereon
WO2009045412A2 (en) * 2007-10-01 2009-04-09 American Diagnostica, Inc. Methods of treatment using modified plasminogen activator inhibitor type-1 molecules
WO2011086557A1 (en) * 2010-01-13 2011-07-21 Thrombotech Ltd. Peptides for the treatment of respiratory diseases
US9597379B1 (en) 2010-02-09 2017-03-21 David Gordon Bermudes Protease inhibitor combination with therapeutic proteins including antibodies
US8771669B1 (en) 2010-02-09 2014-07-08 David Gordon Bermudes Immunization and/or treatment of parasites and infectious agents by live bacteria
US8524220B1 (en) 2010-02-09 2013-09-03 David Gordon Bermudes Protease inhibitor: protease sensitivity expression system composition and methods improving the therapeutic activity and specificity of proteins delivered by bacteria
WO2011139974A2 (en) * 2010-05-03 2011-11-10 Abbott Laboratories Anti-pai-1 antibodies and methods of use thereof
US9737592B1 (en) 2014-02-14 2017-08-22 David Gordon Bermudes Topical and orally administered protease inhibitors and bacterial vectors for the treatment of disorders and methods of treatment
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
EP4061956A4 (de) * 2019-11-21 2023-11-01 The Regents Of The University Of Michigan Polypeptid-inhibitoren von neutrophiler elastase-aktivität und verwendungen davon

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4554101A (en) * 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
US4980286A (en) * 1985-07-05 1990-12-25 Whitehead Institute For Biomedical Research In vivo introduction and expression of foreign genetic material in epithelial cells
US4946778A (en) * 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5679350A (en) * 1992-05-28 1997-10-21 The University Of Toledo Method of delivery of a medicament to a cancer cell using a pathway of plasminogen activator material
US5635493A (en) * 1993-12-01 1997-06-03 Marine Polymer Technologies, Inc. Methods and compositions for poly-β-1-4-N-acetylglucosamine chemotherapeutics
US5639726A (en) * 1994-09-30 1997-06-17 The Regents Of The University Of Michigan Peptide mediated enhancement of thrombolysis methods and compositions
US6103498A (en) 1996-04-12 2000-08-15 American National Red Cross Mutant plasminogen activator-inhibitor type 1 (PAI-1) and uses thereof
US6303338B1 (en) 1996-08-16 2001-10-16 Human Genome Sciences, Inc. Pancreas-derived plasminogen activator inhibitor
ATE421528T1 (de) * 2002-03-04 2009-02-15 Ohio Med College Modifizierter typ-1-plasminogenaktivatorinhibitor und darauf beruhende verfahren
AU2005296064A1 (en) * 2004-10-04 2006-04-27 Trinity Biosystems, Inc. Methods and compositions for needleless delivery of macromolecules
WO2009014564A2 (en) * 2007-04-27 2009-01-29 The University Of Toledo Modified plasminogen activator inhibitor type-1 molecule and methods based thereon

Also Published As

Publication number Publication date
CA2481556C (en) 2014-04-29
US20100137209A1 (en) 2010-06-03
CA2481556A1 (en) 2003-10-02
EP1487867A4 (de) 2006-05-31
AU2003243134A1 (en) 2003-10-08
WO2003080646A3 (en) 2004-04-08
ATE421528T1 (de) 2009-02-15
EP1487867B1 (de) 2009-01-21
EP1487867A2 (de) 2004-12-22
US20050158295A1 (en) 2005-07-21
WO2003080646A2 (en) 2003-10-02
US7592422B2 (en) 2009-09-22

Similar Documents

Publication Publication Date Title
DE60325946D1 (de) Modifizierter typ-1-plasminogenaktivatorinhibitor und darauf beruhende verfahren
Adler et al. Crystal structures of two potent nonamidine inhibitors bound to factor Xa
EA200501017A1 (ru) Астма и модуляторы аллергических воспалений
EA200400971A1 (ru) Фторзамещенные циклоалканоиндолы, композиции, содержащие такие соединения, и способы лечения
EA200100992A1 (ru) Ингибиторы фермента impdh
EA200500299A1 (ru) Пиразольные композиции, используемые в качестве ингибиторов gsk-3
DE69904511D1 (de) Proteinmaterial mit verlangsamtem verdaungsablauf und deren verwendung
MEP53308A (en) Novel peptides that bind to the erythropoietin receptor
ATE279430T1 (de) Verfahren zur verbesserung der serum halbwertszeit von biologisch aktiven molekülen
EA200401541A1 (ru) АМИДЫ ЗАМЕЩЁННЫХ 3-АМИНОТИЕНО [2,3-b]ПИРИДИН-2-КАРБОНОВЫХ КИСЛОТ, СПОСОБЫ ИХ ПОЛУЧЕНИЯ И ПРИМЕНЕНИЯ
NO20052595L (no) Sammensetninger anvendelige som inhibitorer av ROCK- og andre proteinkinaser.
TR200103336T2 (tr) Amid türevleri.
CY1107342T1 (el) Χρηση παραγωγων νιτριλιου ως φαρμακο
BRPI0814220A2 (pt) Purificação de fator viii usando uma resina multimodal ou de modo misto
NO20051847L (no) Eikosapentaensyre (EPA) for behandling av anoreksia nevrosa (AN) og bulimi.
Suzuki Activated protein C inhibitor
De et al. Ubiquitin-like protein from human placental extract exhibits collagenase activity
Taddese et al. In vitro degradation of human tropoelastin by MMP-12 and the generation of matrikines from domain 24
Yoshida et al. Characterization of an apparently lower molecular weight gamma-chain variant in fibrinogen Kyoto I. The replacement of gamma-asparagine 308 by lysine which causes accelerated cleavage of fragment D1 by plasmin and the generation of a new plasmin cleavage site.
ES2113878T3 (es) Proteina c hibrida.
Lee et al. Crosslinking of α2‐Antiplasmin to Fibrin
Yamasaki et al. Inhibition of membrane-type serine protease 1/matriptase by natural and synthetic protease inhibitors
He et al. Mechanical stretch promotes the osteogenic differentiation of bone mesenchymal stem cells induced by erythropoietin
JP5053435B2 (ja) Ｖｗｆプロペプチドから成熟ｖｗｆを産生するための方法。
Banfield et al. Evolution of prothrombin: isolation and characterization of the cDNAs encoding chicken and hagfish prothrombin

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: UNIVERSITY OF TOLEDO, TOLEDO, OHIO, US